SecinH3

A cell-permeable triazolo compound that acts as a Sec7 domain-binding (K_d ≤250 nM for Sec7 from human cytohesins 1-3), selective antagonist against cytohesin family small GEFs (IC₅₀ ≤5.6 µM in ARF1 GDP/GTP exchange assays using human cytohesin 3, as well as murine and Drosophila homologues). It inhibits large GEFs only at much higher concentrations (IC₅₀ ≥65 µM in GDP/GTP exchange assays using hEFA6-S7 and yGea2-S7) and exhibits little activity against a panel of 10 commonly studied kinases or hSosII. Shown to effectively inhibit insulin signaling both in HepG2 cells in vitro and in Drosophila and mice in vivo.

Kd ≤250 nM for Sec7 from human cytohesins 1-3; IC50 ≤5.6 µM in ARF1 GDP/GTP exchange assays using human cytohesin 3, as well as murine and Drosophila homologues

Primary Target
Cytohesin

Toxicity: Irritant (B)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Hafner, M., et al. 2006. Nature444, 941.
Fuss, B., et al. 2006. Nature444, 945.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany